ABSTRACT
Clinical islet transplantation (CIT) and the prospect of a minimally invasive cure for Type 1 diabetes (T1DM) is an alluring prospect for patients and their families. However, the potential demand far outstrips the supply of donor pancreata, while recipients must take immunosuppression life-long. Thus it remains necessary to develop selection criteria to identify suitable candidates for CIT.
